explore -WSS

explore

author：leisure time 2025-09-07 21:56:20 - browse：414

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The Readout: Lenmeldy, GLP

leisure time

focus

WSS

Covid hospitalizations on the rise, Humana says

The 10 drugs up first for Medicare price negotiation

Supreme Court mifepristone arguments center on docs' right to sue

A rare thyroid diagnosis led to unexpected, all

House transparency, PBM reform bill gains bipartisan support

Snackable artificial intelligence, expert AI, and the pharma industry

hotspot

explore

The next ALS data readout — overdue but important

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Amazon on where the company's health care bets are headed next

Duchenne breakthrough therapy leaves behind pioneering families

How to protect patients from sexual assault

Psychedelics group wrestles with new pharma identity

Covid hospitalizations on the rise, Humana says

DIEP, the 'gold standard' of breast reconstruction, is under threat

Eliminate the waiting period for sterilization covered by Medicaid

Cancer drug shortages should be causing more outrage

There's no autism epidemic. It's an autism diagnosis epidemic

explore

Primary care physicians play key roles in Alzheimer's management

Why Novartis is changing the name of its research labs

How to fix cancer clinical trials' diversity problem

Oprah kicked off a national conversation on obesity. Let's have it

Roche subsidiary Foundation Medicine opens new headquarters

AstraZeneca chief proposes a novel edit to the drug pricing bill

focus

leisure time

focus

Wikipedia